Home › Research › Tau biomarkers
Alzheimer disease pathology and the cerebrospinal fluid proteome
Dayon L, Núñez Galindo A, Wojcik J, Cominetti O, Corthésy J, Oikonomidi A, Henry H, Kussmann M et al.. Alzheimer's research & therapy, 2018-07-18
Topic: Amyloid, tau and blood-test diagnosis
Background Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with AD pathology, amyloid pathology, and tau-related neurodegeneration have not yet been fully explored. Using a robust automated MS-based proteomic biomarker discovery workflow, we measured cerebrospinal fluid (CSF) proteomes to explore their association with well-established markers of core AD pathology. Methods Cross-sectional analysis was performed on CSF collected from 120 older community-dwelling adults with normal (n = 48) or impaired cognition (n = 72).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., et al. (2018). Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-018-0397-4
Vancouver
Dayon L, Núñez Galindo A, Wojcik J, Cominetti O, Corthésy J, Oikonomidi A, et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimer's research & therapy. 2018. doi:10.1186/s13195-018-0397-4. PMID: 30021611.
BibTeX
@article{dayon2018-30021611,
author = {Dayon, L. and Núñez Galindo, A. and Wojcik, J. and Cominetti, O. and Corthésy, J. and Oikonomidi, A. and Henry, H. and Kussmann, M. and others},
title = {{Alzheimer disease pathology and the cerebrospinal fluid proteome}},
journal = {Alzheimer's research \& therapy},
year = {2018},
doi = {10.1186/s13195-018-0397-4},
pmid = {30021611},
url = {https://doi.org/10.1186/s13195-018-0397-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Using a robust automated MS-based proteomic biomarker discovery workflow, we measured cerebrospinal fluid (CSF) proteomes to explore their association with well-established markers of core AD pathology.
- Methods Cross-sectional analysis was performed on CSF collected from 120 older community-dwelling adults with normal (n = 48) or impaired cognition (n = 72).
- LC-MS quantified hundreds of proteins in the CSF.
- CSF concentrations of β-amyloid 1-42 (Aβ 1-42 ), tau, and tau phosphorylated at threonine 181 (P-tau181) were determined with immunoassays.
Why it matters
This cross-sectional analysis measured hundreds of CSF proteins in 120 older adults with normal or impaired cognition to explore their association with core Alzheimer's pathology markers. It is a biomarker discovery study and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants48
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 48 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 105 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.5 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 3 / 6 | Cited 6.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Julius Popp: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Centre Hospitalier Universitaire Vaudois: institution h-index 806 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30021611) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-018-0397-4
- PubMed: 30021611
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.